What Rigevidon is and why side effects can occur
Rigevidon is a prescription-only combined oral contraceptive available in the United Kingdom. Each tablet contains two active hormones: 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol. Together, these components work primarily by suppressing ovulation, thickening cervical mucus to block sperm, and thinning the uterine lining to prevent implantation.
Side effects arise because the body reacts to these external hormones. The added levonorgestrel and ethinylestradiol shift the natural hormonal balance, which can influence various bodily systems including mood, fluid retention, blood vessel tone, and metabolism. Because individual sensitivity to these chemical changes varies significantly, experiences differ from person to person.
Distinguish between reported effects and proven causation. While many side effects listed in official product information are statistically associated with the medication, they do not automatically mean the pill caused every instance of that symptom in every user. Some symptoms may coincide with other life factors or underlying health conditions. The relationship between the hormone levels and a specific physical or emotional response is complex and highly individual.
This guide distinguishes between common, inconvenient effects that often settle with time and rare but serious complications that require immediate medical attention. Understanding this distinction helps in monitoring health effectively without causing unnecessary alarm for transient symptoms.
Common Rigevidon side effects
The UK product information classifies specific adverse reactions as “common,” a regulatory term indicating they may affect at least one in 100 users but fewer than one in 10. This frequency range helps contextualise how often these events occur, though it does not guarantee that every individual will experience them, nor does it prove the medication caused every instance of a listed symptom.
These common effects can be grouped into several categories for clarity:
Gastrointestinal and General Discomfort Nausea, vomiting, abdominal pain, and general fluid retention (oedema) are frequently reported. These symptoms often reflect the body's initial adjustment to hormonal changes rather than a toxic reaction. Taking the tablet with food or at bedtime may help mitigate gastrointestinal upset for some users.
Neurological and Emotional Responses Some individuals experience nervousness, dizziness, or mood swings. As detailed in later sections, depression is also listed as a common effect, though its interpretation requires careful consideration of individual history.
Breast and Reproductive System Changes Breast pain, tenderness, swelling, or secretions are common due to hormonal stimulation of breast tissue. Changes to the vaginal environment may lead to vaginitis, including vaginal candidiasis (thrush), or altered vaginal secretions.
Metabolic and Dermatological Effects Weight increase or decrease and acne are both classified as common. Individual responses vary widely; some users report weight fluctuations while others do not, and acne may improve or worsen depending on personal hormonal sensitivity.
The presence of these effects in official documentation reflects reporting frequency within studied populations. They represent potential reactions that users should be aware of, rather than inevitable outcomes. For many, these symptoms are manageable or transient, while for others, they may persist and require clinical review.
Understanding Rigevidon: Key Distinctions
Bleeding and period changes
Distinguish between a natural menstrual period and the withdrawal bleed that occurs during the pill-free interval of combined oral contraceptives. Rigevidon thins the lining of the uterus, which often results in lighter, shorter, or less painful bleeding than what occurs with a natural cycle. In some cases, the uterine lining may become so thin that no bleeding occurs at all during the hormone-free week; this is known as an absence of withdrawal bleed and is listed as a common reported effect.
Irregular spotting or breakthrough bleeding-bleeding between scheduled periods-is particularly common during the first three months after starting Rigevidon or switching to it from another contraceptive method. The UK product information describes this initial period as an adaptation phase, suggesting that approximately three cycles are needed for the body to adjust to the hormonal levels before evaluating the stability of bleeding patterns. During this time, light spotting is frequent and usually not a sign that the medication has failed, provided pills are taken correctly.
Certain bleeding patterns warrant clinical review rather than simple observation. Bleeding that begins after a period of previously regular cycles may indicate non-hormonal causes, including pregnancy or other underlying conditions, rather than just an adjustment to the pill. Persistent irregular bleeding that continues beyond the initial three-month adaptation window, or heavy bleeding that disrupts daily life, should be assessed by a healthcare professional. Clinicians may investigate whether the current formulation is suitable or if alternative factors are contributing to the changes.
While bleeding pattern modifications are expected and often benign, they do not necessarily reflect contraceptive efficacy in isolation. If breakthrough bleeding occurs, users should continue taking their tablets as scheduled. Any concern about pregnancy risk due to missed pills or severe vomiting requires separate guidance, but for those taking the medication consistently, a change in bleeding flow is primarily a reflection of the uterine lining's response to the hormones rather than a failure of contraception.
Mood changes, depression and libido
Mood swings, including depression, and altered libido are classified as common adverse effects in the Rigevidon product information. These reports reflect documented patient experiences and clinical observations, acknowledging that hormonal contraceptives can influence emotional states and sexual drive in some individuals. Interpreting these effects requires distinguishing between individual reported symptoms and broader population-level evidence.
Official NHS guidance notes that while some combined-pill users report mood changes, headaches, nausea, dizziness, or sore breasts, there is currently no conclusive evidence that the combined pill directly causes weight gain or changes sex drive in the general population. This creates a distinction between anecdotal reports of distress and statistical causation. While many users may experience temporary emotional shifts or fluctuations in libido as their bodies adjust to the hormonal formulation, these are not universal outcomes, nor do they imply that every instance of low mood or reduced sexual interest is caused by the medication.
Despite the lack of definitive causal proof for widespread libido changes, the Rigevidon label explicitly states that depressed mood and depression are known undesirable effects of hormonal contraceptives. The guidance emphasises that depression can be serious and advises users to contact their physician about any mood changes or depressive symptoms, including shortly after starting treatment. This recommendation applies regardless of whether evidence suggests a direct causal link for the entire population; individual susceptibility varies, and new or worsening mental health symptoms should never be ignored or dismissed as merely an “adjustment phase.”
Users experiencing persistent low mood, anxiety, or significant changes in sexual desire that affect their quality of life should discuss these concerns with a clinician. Avoid self-diagnosing the cause or making unilateral decisions to stop or switch medication without professional guidance. A healthcare provider can help determine whether the symptoms are related to the contraceptive formulation, underlying health conditions, or other life factors, and can suggest appropriate management strategies.
The presence of these effects in medical literature serves as a warning sign rather than a prediction. Not everyone will experience mood disturbances or libido changes, but those who do have access to established protocols for seeking help. Prioritising mental well-being alongside physical health ensures that any adverse reactions are managed promptly and appropriately, rather than endured unnecessarily during the initial adjustment period.
Weight, acne and other commonly reported effects
Reconciling reports of weight changes requires distinguishing between official product information and broader public health guidance. The Rigevidon label lists both weight increase and weight decrease as common reported adverse effects, alongside fluid retention or oedema. These fluctuations often reflect the body's adjustment to hormonal levels or temporary water retention rather than significant changes in body fat.
NHS guidance states there is no evidence that the combined pill causes weight gain in the general population. This apparent contradiction highlights the difference between individual reported experiences and established causal links for the wider population. While some users may notice shifts in their scale weight or how their clothes fit due to fluid balance, this does not equate to permanent fat accumulation caused by the medication.
Acne presents a similar nuance. It is classified as a common adverse effect on the Rigevidon label, meaning some users may experience breakouts or changes in skin texture. Hormonal contraceptives are sometimes prescribed specifically to help manage acne in other contexts. Outcomes vary significantly based on individual hormonal sensitivity; for some, skin may improve, while for others, it may worsen during the initial months. There is no guarantee of improvement or deterioration, and skin changes should be monitored alongside other physical symptoms.
Beyond these frequently cited concerns, the label identifies several uncommon effects that affect at least one in 1,000 but fewer than one in 100 users. These include altered appetite, abdominal cramps, bloating, and skin reactions such as rashes or chloasma (dark patches on the skin). Hair changes are also noted, with both excessive hair growth and hair loss listed as potential uncommon effects.
Interpret commercial self-reported reviews with caution. Percentages from online forums or non-clinical surveys do not constitute clinical incidence rates and cannot be used to prove that Rigevidon uniquely causes more side effects than other equivalent combined pills. Individual experiences are real, but they represent a slice of the population rather than a universal rule. For most users, these effects are manageable, though persistent discomfort should be discussed with a healthcare professional to determine if an alternative method is more suitable.
Blood clots and other serious warning signs
Any combined hormonal contraceptive, including Rigevidon, increases the risk of venous thromboembolism (VTE) compared with not using the medication at all. The UK product information estimates that there are about two VTE cases per 10,000 non-pregnant non-users per year, versus about six cases per 10,000 users per year for a levonorgestrel-containing combined hormonal contraceptive. These are population estimates and do not predict an individual's specific risk. Levonorgestrel-containing products such as Rigevidon are among the combined hormonal contraceptives associated with the lowest VTE risk.
The risk of developing a blood clot is generally higher during the first year of using any combined pill and may rise again if you restart the medication after a break of four weeks or more. While serious events are rare, it is crucial to recognise the symptoms that could indicate a deep vein thrombosis (DVT), pulmonary embolism, stroke, or heart attack.
Possible symptoms of DVT include one-sided leg or foot swelling, leg pain or tenderness, warmth, and red or discoloured skin. Signs of a pulmonary embolism may involve sudden unexplained breathlessness or rapid breathing, a sudden cough that may involve blood, sharp chest pain, severe light-headedness or dizziness, and a rapid or irregular heartbeat.
Symptoms suggesting a stroke include sudden one-sided weakness, speech or vision disturbance, loss of balance, or a severe unexplained headache. Chest pressure or pain accompanied by breathlessness or other systemic symptoms can indicate a myocardial infarction.
If you experience any of these symptoms, seek urgent medical attention immediately. Inform healthcare providers that you are using a combined hormonal contraceptive, as this information significantly influences their assessment and treatment decisions. These warning signs require prompt clinical evaluation rather than observation or self-management.
Factors that can make Rigevidon unsuitable or increase risk
Certain health conditions and lifestyle factors can make Rigevidon contraindicated or significantly increase the risk of serious adverse events, particularly thrombosis. Clinical suitability requires an assessment of these individual risk profiles, as multiple factors can combine to elevate danger beyond acceptable levels.
Rigevidon must not be used if you have a current or previous history of venous thromboembolism (VTE), including deep vein thrombosis or pulmonary embolism. It is also contraindicated in individuals with specified inherited or acquired predispositions to blood clotting, known or suspected hormone-dependent malignancies, severe liver disease, or liver tumours. Unexplained vaginal bleeding must be investigated before initiating therapy, as it may indicate an underlying condition that the pill could exacerbate.
Arterial risks also preclude use. Current or previous arterial thromboembolism, stroke, or migraine with focal neurological symptoms are absolute contraindications. Women with a serious or combined high arterial-risk profile should not use this medication.
Specific factors substantially increase the risk of thrombotic events and require careful clinical evaluation:
- Age and Smoking: The label strongly advises that women over 35 who continue to smoke use a different contraceptive method, as smoking combined with estrogen significantly raises arterial and venous clot risks.
- Obesity: Increased body mass index is associated with higher baseline thrombotic risk.
- Family History: A relevant family history of premature clotting events may indicate an undiagnosed genetic predisposition.
- Immobilisation: Prolonged immobilisation, such as during major surgery or extended bed rest, temporarily elevates VTE risk to a level where combined hormonal contraceptives are generally unsuitable.
Because risk can rise substantially when multiple factors coexist, individual suitability cannot be decided based on one characteristic alone. A clinician must assess the complete medical and family history to determine if Rigevidon is safe or if an alternative contraceptive method with a lower thrombotic profile is more appropriate.
How long side effects may last and when to seek advice
The initial period after starting Rigevidon or switching from another contraceptive method involves an adjustment phase where the body adapts to new hormonal levels. The UK product information suggests that approximately three cycles are needed before evaluating bleeding patterns. During this time, irregular spotting, breakthrough bleeding, nausea, breast tenderness, and mild mood swings are common. For many users, these symptoms gradually diminish or resolve completely as the uterine lining stabilises and the body becomes accustomed to the medication.
Three months is a review point rather than a rule that requires enduring severe, worsening, or dangerous symptoms for the entire duration. Persistent or troublesome effects that do not settle within this window merit clinical discussion. The NHS advises speaking to a doctor or pharmacist if side effects remain bothersome after three months, as an alternative formulation may be more suitable and better tolerated.
Escalation of care should be guided by the nature of the symptom:
- Persistent Common Effects: If common side effects such as mood changes, libido issues, or ongoing irregular bleeding continue beyond three months and impact quality of life, contact a clinician for assessment and potential method switching.
- Depressive Symptoms: New or worsening depressive symptoms, anxiety, or severe mood swings warrant prompt contact with a healthcare provider, regardless of the time elapsed since starting treatment. These should not be dismissed as temporary adjustment issues if they are significant.
- Serious Warning Signs: Any symptom suggesting a blood clot, stroke, heart attack, or other serious complication requires immediate urgent medical attention. Do not wait for an adaptation period to pass; seek emergency care immediately if such symptoms arise.
A clinician may discuss switching to a different combined oral contraceptive with a distinct hormone profile or considering non-hormonal alternatives based on your specific health history and side effect profile. Decisions regarding stopping, restarting, or altering the regimen must be made in consultation with a healthcare professional to ensure continued effective contraception and safety.
Rigevidon is a prescription-only combined oral contraceptive available in the UK, containing levonorgestrel and ethinylestradiol. Side effects can occur as the body adjusts to these hormones, but official reports show statistical associations rather than proving the pill caused every symptom in every user. Common effects, classified as affecting at least 1 in 100 but fewer than 1 in 10 users, include nausea, vomiting, abdominal pain, fluid retention, nervousness, dizziness, mood swings, depression, breast pain or tenderness, vaginal infections or altered secretions, weight increase or decrease, and acne. Bleeding changes are common, especially spotting or breakthrough bleeding in the first three months, and the withdrawal bleed may be absent. NHS guidance states there is no conclusive evidence that the combined pill directly causes weight gain or changes sex drive in the general population, though the label lists depressed mood and depression as known undesirable effects and advises contacting a physician about mood changes.
Any combined hormonal contraceptive, including Rigevidon, increases the risk of venous thromboembolism compared with not using it, although levonorgestrel-containing products are among those with the lowest VTE risk. Risk is generally higher during the first year and may rise again if the medication is restarted after a break of four weeks or more. Urgent medical attention is needed for possible signs of a blood clot, pulmonary embolism, stroke, or heart attack, such as one-sided leg or foot swelling, pain, warmth, or discoloured skin; sudden unexplained breathlessness or rapid breathing; a sudden cough that may involve blood; sharp chest pain; severe light-headedness or dizziness; a rapid or irregular heartbeat; sudden one-sided weakness; speech or vision disturbance; loss of balance; a severe unexplained headache; or chest pressure or pain with breathlessness. Tell healthcare providers that you are using a combined hormonal contraceptive.
Rigevidon must not be used with a current or previous history of venous thromboembolism, certain inherited or acquired clotting predispositions, known or suspected hormone-dependent malignancies, severe liver disease or liver tumours, or unexplained vaginal bleeding before it is investigated. It is also contraindicated with current or previous arterial thromboembolism, stroke, or migraine with focal neurological symptoms. Age over 35 with continued smoking, obesity, a relevant family history of premature clotting, and prolonged immobilisation can substantially increase risk, so suitability needs full clinical assessment. About three cycles is an adjustment and review point, not a reason to endure severe, worsening, or dangerous symptoms. Persistent troublesome common effects after three months should be discussed with a clinician; new or worsening depressive symptoms, anxiety, or severe mood swings warrant prompt contact regardless of timing; serious warning signs require immediate urgent care. Stopping, restarting, or switching should be decided with a healthcare professional.
Source organization: electronic Medicines Compendium
Source organization: electronic Medicines Compendium
Source organization: NHS
Questions & comments
Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.